of weight change investigated potential explanatory variables between the sexes, such as diabetic status (CFRD) and FS. Results Cross-sectional Boys 13-15 years had lower mean BMIP than girls (41.2 vs 50.5 p<0.001). Boys had a lower Zscore than girls for age 13-23 years. Mean BMI was significantly lower in females (21.9 vs 22.5 p<0.001). More females were underweight (BMI <19) than males (18.9% vs 14.0% p<0.001), this was specifically observed in ages24 years. Underweight individuals died younger than individuals with BMI 19 (29.3 years vs 36.0 years p=0.007). Lower weight was associated with more IVAbx days. Males had higher rates of FS (34.7% vs 28.9% in females p<0.001) specifically when16 years. These sex differences were not explained by differences in ethnicity, genotype or socio-economic status. Longitudinal Boys had a greater fall in BMIP (8.3 vs 4.1 in females p=0.002). In adulthood, females had significantly less increase in BMI (0.20 vs 0.57 in males p<0.001). FEV 1 decline was greater in females (7.4% vs 5.9% in males p=0.0016) not receiving FS, with no difference in change in FEV 1 between the sexes in those receiving FS. Conclusion From 16 years boys changed from having lower BMIP to higher mean BMI and lower rates of underweight status in adulthood. Higher rates of FS in adolescent boys might explain this. Lower weight is associated with earlier death and increased IVABx use. In individuals without FS females have a greater decline in FEV 1 than males, this is not seen in individuals on FS. This has not been previously shown and warrants further analysis.
Managing pleural disease: from intervention to conservation Introduction Malignant Pleural Mesothelioma (MPM) is the only malignancy which develops primarily in the pleural space and is a common cause of a malignant pleural effusion (MPE). MPE associated with MPM is managed similarly to any other malignancy, but it is unclear if the underlying mechanisms of fluid accumulation are the same and whether different treatment strategies should therefore be employed. The TIME 1 trial enrolled patients with MPE who underwent pleurodesis. This post hoc analysis compares the outcomes of patients with MPM to the rest of the trial population.
Methods 298 patients had available data on their final diagnosis. A number of different variables were compared, including pleurodesis success, systemic inflammation, the prevalence of trapped lung, total fluid volume drained and baseline pain Visual Analogue Score (VAS). Results Of the 298 patients included in the analysis 110 patients had mesothelioma (36.9%). Post pleurodesis, MPM patients had a significantly greater rise in CRP than those with other underlying pathologies but had a significantly lower rate of successful pleurodesis. Patients with MPM had a lower pain VAS score on enrolment. There was no significant difference in the rates of trapped lung, the total volume of pleural fluid drained or the change in White Cell Count (WCC) between the groups. Conclusion There are significant differences in the outcomes of patients with MPM and those with other MPE. Patients with MPM had a lower pleurodesis rate but a significantly greater change in C-reactive protein levels post pleurodesis, signifying a higher inflammatory response to pleurodesis, which has been assumed to associate with pleurodesis success. The mechanisms causing the increased inflammatory response in MPM are unclear. The basis for the lower rates of pleurodesis is unexplained, especially as there was no significant different in the rates of trapped lung. Patients with MPM had a lower level of pain VAS scores on enrolment but further analyses are needed to determine whether this is clinically relevant and reproducible. These data indicate that MPM behaves differently to other forms of MPE and treatment strategies should be tailored towards MPM as a separate entity. 
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